UA94032C2 - Жидкая стабализированная композиция интерферона без hsa - Google Patents

Жидкая стабализированная композиция интерферона без hsa

Info

Publication number
UA94032C2
UA94032C2 UAA200704143A UAA200704143A UA94032C2 UA 94032 C2 UA94032 C2 UA 94032C2 UA A200704143 A UAA200704143 A UA A200704143A UA A200704143 A UAA200704143 A UA A200704143A UA 94032 C2 UA94032 C2 UA 94032C2
Authority
UA
Ukraine
Prior art keywords
liquid formulations
stabilized interferon
interferon
interferon liquid
stabilized
Prior art date
Application number
UAA200704143A
Other languages
English (en)
Ukrainian (uk)
Inventor
Фабрицио Самаритани
Рио Алессандра Дель
Original Assignee
Эйрес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйрес Трейдинг С.А. filed Critical Эйрес Трейдинг С.А.
Publication of UA94032C2 publication Critical patent/UA94032C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается стабилизированной жидкой фармацевтической композиции без HSA, содержащей интерферон-бета (IFN-бета), которая представляет собой раствор, содержащий буфер, поверхностно-активное вещество, каким является полоксамер 188, изотонический агент, бактериостатический препарат, которым является бензиловый спирт, и антиоксидант, которым является метионин.
UAA200704143A 2003-05-01 2004-04-29 Жидкая стабализированная композиция интерферона без hsa UA94032C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03101210 2003-05-01

Publications (1)

Publication Number Publication Date
UA94032C2 true UA94032C2 (ru) 2011-04-11

Family

ID=36908159

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200509798A UA80331C2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilised interferon liquid formulations
UAA200704143A UA94032C2 (ru) 2003-05-01 2004-04-29 Жидкая стабализированная композиция интерферона без hsa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA200509798A UA80331C2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilised interferon liquid formulations

Country Status (28)

Country Link
US (1) US8309069B2 (ru)
EP (1) EP1617861B1 (ru)
JP (2) JP4870550B2 (ru)
KR (1) KR101116058B1 (ru)
CN (1) CN1816347B (ru)
AR (1) AR044147A1 (ru)
AU (2) AU2004233603B2 (ru)
BR (1) BRPI0410488B8 (ru)
CA (1) CA2521560A1 (ru)
DK (1) DK1617861T3 (ru)
EA (2) EA009995B1 (ru)
ES (1) ES2417061T3 (ru)
HR (1) HRP20130512T1 (ru)
IL (1) IL171709A (ru)
ME (1) ME00404B (ru)
MX (1) MXPA05011718A (ru)
MY (1) MY151121A (ru)
NO (1) NO335674B1 (ru)
NZ (2) NZ542912A (ru)
PL (1) PL1617861T3 (ru)
PT (1) PT1617861E (ru)
RS (1) RS52869B (ru)
SG (1) SG159389A1 (ru)
SI (1) SI1617861T1 (ru)
TW (1) TWI272948B (ru)
UA (2) UA80331C2 (ru)
WO (1) WO2004096263A2 (ru)
ZA (2) ZA200508124B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846427B2 (en) * 2003-12-11 2010-12-07 Ares Trading S.A. Stabilized interferon liquid formulations
ZA200609412B (en) * 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
EP1750751B1 (en) * 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
BRPI0510527A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
JP4897814B2 (ja) * 2005-09-14 2012-03-14 アレス トレーディング ソシエテ アノニム ポロキサマーの定量方法
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
HUE033256T2 (hu) 2007-03-30 2017-11-28 Xisle Pharma Ventures Trust Kétfázisú lipidvezikulum készítmény és eljárás cervikális diszplázia kezelésére intravaginális adagolással
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
ES2387236T3 (es) * 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
KR20150074167A (ko) 2012-10-26 2015-07-01 루핀 리미티드 Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
CN107073080A (zh) * 2014-09-23 2017-08-18 豪夫迈·罗氏有限公司 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
KR20240118230A (ko) * 2023-01-26 2024-08-05 에이비온 주식회사 인터페론 베타 건조 분말 제제 및 이의 제조방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
KR101042660B1 (ko) 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DE59805732D1 (de) * 1997-09-23 2002-10-31 Rentschler Biotech Gmbh Flüssige interferon-beta-formulierungen
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
BR9910023A (pt) 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
EP1852424B1 (de) * 1998-05-11 2012-04-04 Basf Se Verfahren zur Herstellung von Isoxazolin-3-YL-Acylbenzolen
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
US7846427B2 (en) 2003-12-11 2010-12-07 Ares Trading S.A. Stabilized interferon liquid formulations
ZA200609412B (en) 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas

Also Published As

Publication number Publication date
SG159389A1 (en) 2010-03-30
WO2004096263A3 (en) 2004-12-02
BRPI0410488B8 (pt) 2021-09-08
BRPI0410488A (pt) 2006-06-13
JP2006525280A (ja) 2006-11-09
NZ542912A (en) 2008-04-30
HRP20130512T1 (hr) 2013-07-31
WO2004096263A2 (en) 2004-11-11
KR20060011976A (ko) 2006-02-06
AR044147A1 (es) 2005-08-24
IL171709A (en) 2016-03-31
CN1816347B (zh) 2010-07-21
TWI272948B (en) 2007-02-11
TW200503754A (en) 2005-02-01
RS52869B (sr) 2013-12-31
AU2004233603A1 (en) 2004-11-11
NO20055666L (no) 2005-11-30
RS20050821A (sr) 2007-12-31
EA009995B1 (ru) 2008-06-30
MXPA05011718A (es) 2006-01-23
ME00404B (me) 2011-10-10
PT1617861E (pt) 2013-08-28
UA80331C2 (en) 2007-09-10
MEP60408A (en) 2011-05-10
JP2011225599A (ja) 2011-11-10
HK1088847A1 (zh) 2006-11-17
BRPI0410488B1 (pt) 2021-06-22
EP1617861A2 (en) 2006-01-25
ES2417061T3 (es) 2013-08-05
DK1617861T3 (da) 2013-07-29
NZ566625A (en) 2010-02-26
KR101116058B1 (ko) 2012-04-12
EA200800327A1 (ru) 2008-10-30
AU2004233603B2 (en) 2009-02-26
PL1617861T3 (pl) 2013-10-31
CN1816347A (zh) 2006-08-09
AU2009201261A1 (en) 2009-04-23
EA200501699A1 (ru) 2006-06-30
ZA200708484B (en) 2008-10-29
NO335674B1 (no) 2015-01-19
MY151121A (en) 2014-04-30
JP5346065B2 (ja) 2013-11-20
EP1617861B1 (en) 2013-05-29
US20070059285A1 (en) 2007-03-15
CA2521560A1 (en) 2004-11-11
SI1617861T1 (sl) 2013-09-30
JP4870550B2 (ja) 2012-02-08
ZA200508124B (en) 2009-02-25
US8309069B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
UA94032C2 (ru) Жидкая стабализированная композиция интерферона без hsa
NO20065860L (no) Stabiliserte flytende interferonformuleringer
UA93349C2 (ru) Способ стабилизации мономерного белка интерферона
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
MY142354A (en) Acidic insulin preparations having improved stability
PT1412384E (pt) Formulação estável de glp-1 modificado
TW200735897A (en) HFSH aqueous formulation
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
NZ593190A (en) Factor viii formulations
CY1112193T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης
HRP20100727T1 (hr) Tekući ili liofilizirani farmaceutski pripravci fsh i/ili lh zajedno s neionskim tenzidom poloksamer 188 i bakteriostatskim sredstvom
IL206441A0 (en) Peg-interferon-beta formulations and their preparation
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
AR034749A1 (es) Formulaciones de interferon beta humano
WO2003013441A3 (en) Levothyroxine compositions and methods
TW200501977A (en) Stabilized composition comprising protein
WO2004014318A3 (en) Levothyroxine compositions and methods
TH102367B (th) สูตรผสมอินเตอร์เฟียรอนที่เป็นของเหลวซึ่งถูกทำให้เสถียรโดยปลอด hsa
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
CY1114273T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη